Clinical Research
Filter News
Found 119,841 articles
-
Biopharma companies focused on oncology continue to release data that will be presented at the 2020 virtual meeting of the European Society of Medical Oncology.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 18, 2020.
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
Octreotide, a somatostatin analog, significantly inhibits growth hormone, one of the key drivers of acromegaly.
-
HSS Funds Innovative Research on COVID-19
9/18/2020
Thanks to the generous support of donors, Hospital for Special Surgery (HSS) has announced the funding of nine grants for projects related to the study of COVID-19.
-
IMFINZI Demonstrated Unprecedented Survival in Unresectable Stage III Non-small Cell Lung Cancer With an Estimated 50% of Patients Surviving Four Years
9/18/2020
PACIFIC Phase III trial data at ESMO also showed an estimated 35% of non-small cell lung cancer patients treated with IMFINZI® had not progressed after four years
-
Experimental Drug Blocks COVID-19 Viral Entry into Lung Cells
9/18/2020
An experimental compound prevents the virus that causes COVID-19 from entering human airway cells, a new study finds. Posted online recently on the pre-print server bioRxiv , the work revolves aroun
-
Radiation Business Solutions Acquires RADMAX, Inc., Introduces VidaCore
9/18/2020
Radiation Business Solutions (RBS) announced that they reached an agreement to purchase RADMAX, Inc., a radiation oncology medical billing company headquartered in Tyler, TX , effective August 31, 2020 . RBS also announced the development of their new, quality-driven radiation oncology network, VidaCore. "In light of th
-
Achieve Life Sciences Announces Results from Evaluation of Cytisinicline (cytisine) versus Chantix® (varenicline) in 5-HT3 Receptor Binding Assay Study
9/18/2020
Provides Mechanistic Rationale for the Clinical Findings that Cytisinicline (Cytisine) Treatment is Associated with Lower Rates of Nausea and Vomiting compared to Chantix
-
National Kidney Foundation Statement on the ESRD Treatment Choices Model (ETC) and Policies to Improve Kidney Patient Choice
9/18/2020
"The National Kidney Foundation (NKF) is pleased to support the three linchpin policies of the Advancing American Kidney Health (AAKH) initiative finalized this morning. On behalf of 37 million adults in the U.S. affected by kidney disease, we e
-
Phosplatin Therapeutics Announces Results from Phase 1b Dose Escalation Study of PT-112 Plus Avelumab in Patients with Solid Tumors
9/18/2020
Phosplatin Therapeutics presented data from a Phase 1b dose escalation study of lead candidate PT-112, an immunogenic cell death inducer, used in combination with avelumab, a PD-L1 immune checkpoint inhibitor, in patients with progressing solid tumors who previously exhausted all available treatment options.
-
Achieve Announces Presentation of Investigator-Led RAUORA Trial Data Demonstrating Significantly Fewer Side Effects with Higher Quit Rates for Cytisinicline (cytisine) Compared to Chantix® (varenicline) in First Head-to-Head Comparative Study
9/18/2020
Subjects in the Cytisinicline Arm Were 55% More Likely to Quit Smoking at 6 Months Compared to Subjects Who Received Varenicline Significantly Fewer Overall Adverse Events Were Reported in Cytisinicline-Treated Subjects (p<0.001) Cytisinicline U.S. Phase 3 Trial Expected to Begin in Fourth Quarter 2020 [18-September-2020] SEATTLE and VANCOUVER,
-
Oncologie Announces New Data and Analyses from Clinical Programs and Name Change to OncXerna Therapeutics
9/18/2020
OncXerna’s RNA-based biomarker platform successfully identified responders versus non-responders in trials with late-stage cancer patients
-
Todos Medical CEO Releases Letter to Shareholders
9/18/2020
Significant progress in establishing COVID-19 PCR-based diagnostic testing business in US 3CL Protease-based saliva test making progress in Israel 3CL Protease inhibitor NLC-001 dietary supplement added to commercial portfolio 2019 convertible note holders and institutional Q1/2020 convertible note holders sign temporary lock-up agreement NEW YORK, REHOVOT, Israel and SINGAPORE, Sept. 18, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (OTCQB: TOMDF) , an in vitro
-
AIkido Pharma Announces Update On Its Use Of Artificial Intelligence
9/18/2020
Development of Products, Tools, and Technologies to Accelerate Development of Key Marker Panels for the Personalized Treatment of PDA
-
Medexus Engages Adelaide Capital for Investor Relations Services and Reports Annual Meeting Results
9/18/2020
Medexus Pharmaceuticals Inc. (the “ Company ” or “Medexus ”) (TSXV: MDP) (OTCQX: MEDXF) is pleased to announce that it has entered into a consulting agreement (the “ Consulting Agreement ”) with Adelaide Capital (“ Adelaide ”) to provide investor relations consulting services to the Company in compliance with the policies and guidelines of the TSX Venture Exchange (the “ TSXV ”) and applicable legislation. Adelaide will
-
Acella Pharmaceuticals, LLC Issues Voluntary Nationwide Recall of Two Lots of NP Thyroid®, Thyroid Tablets, USP Due to Sub Potency
9/18/2020
Acella Pharmaceuticals, LLC is voluntarily recalling one lot of 15-mg and one lot of 120-mg NP Thyroid ® , Thyroid Tablets, USP [levothyroxine (T4) and liothyronine (T3)] to the consumer level. The products are being recalled because testing has found these lots to be sub potent. The product may have as low as 87% of the labeled amount
-
Astellas and Seattle Genetics Announce PADCEV® (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cancer
9/18/2020
Astellas Pharma Inc. and Seattle Genetics, Inc. announced that a phase 3 trial of PADCEV® met its primary endpoint of overall survival compared to chemotherapy.
-
SpringWorks Therapeutics Enters into Sponsored Research Agreement with Fred Hutchinson Cancer Research Center to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple Myeloma
9/18/2020
SpringWorks Therapeutics, Inc. announced that it has entered into a sponsored research agreement with Fred Hutchinson Cancer Research Center to further explore the ability of SpringWorks’ investigational gamma secretase inhibitor, nirogacestat, to modulate B-cell maturation antigen and potentiate BCMA-targeting therapies, including radioimmunotherapies, in a variety of preclinical and patient-derived multiple myeloma models developed by researchers at Fred Hutch.
-
Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal
9/18/2020
Independent central review confirmed responses include 1 complete response, 12 partial responses and 33 stable disease for an objective response rate of 14% and disease control rate of 49%